My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

1.098 -0.012 (-1.08%)

Streaming Delayed Price Updated: 3:49 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Dow Jumps Over 300 Points; Best Buy Profit Beats Views ↗

March 02, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Thursday. The Dow traded up 0.97% to 32,978.95 while the NASDAQ rose 0.59% to 11,446.55. The S&P...

Via Benzinga

Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 02, 2023

Gainers Exela Technologies, Inc. (NASDAQ: XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 02, 2023

Via Benzinga

Dow Rises 100 Points; Macy's Posts Upbeat Earnings ↗

March 02, 2023

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Thursday. The Dow traded up 0.31% to 32,764.50 while the NASDAQ fell 0.49% to 11,324.28. The S&P 500...

Via Benzinga

BioRestorative Therapeutics (BRTX) Stock Soars 40% on Patent News ↗

March 02, 2023

Could more patents translate to more revenue for BioRestorative Therapeutics? It's a question that BRTX stock traders are considering now.

Via InvestorPlace

Wall Street Mixed At Open; US Weekly Jobless Claims Decline ↗

March 02, 2023

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 32,740.88 while the NASDAQ fell 0.58%...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 02, 2023

Via Benzinga

EXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program ↗

March 02, 2023

The United States Patent and Trademark Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program.

Via Benzinga

BioRestorative Therapies: This Biopharma Company Is Helping Your Body Heal Itself ↗

February 16, 2023

Lance Alstodt, Chairman and CEO of BioRestorative Therapies, Inc. (NASDAQ: BRTX), was recently interviewed by Benzinga.

Via Benzinga

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

February 10, 2023

By Julian Richard, Benzinga

Via TheNewswire.com

Topics Intellectual Property

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

February 10, 2023

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

Via News Direct

Topics Intellectual Property

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes ↗

February 10, 2023

BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a...

Via Benzinga

BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program

February 08, 2023

Via Investor Brand Network

Topics Intellectual Property

EXCLUSIVE: BioRestorative Poised To Receive European Patent For ThermoStem Program ↗

February 08, 2023

The European Patent Office has issued a notice of allowance for a patent application related to BioRestorative Therapies Inc's (NASDAQ: BRTX) metabolic ThermoStem program. The notice of allowance was...

Via Benzinga

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results

February 03, 2023

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results

Via News Direct

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results

February 03, 2023

By Julian Richard, Benzinga

Via TheNewswire.com

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗

February 03, 2023

Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...

Via Benzinga

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

January 26, 2023

By Faith Ashmore, Benzinga

Via TheNewswire.com

Topics Intellectual Property

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

January 26, 2023

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

Via News Direct

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗

January 25, 2023

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.

Via Benzinga

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

December 06, 2022

From BioRestorative Therapies, Inc

Via GlobeNewswire

EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome ↗

December 06, 2022

BioRestorative Therapies Inc (NASDAQ: BRTX) has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development...

Via Benzinga

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

December 05, 2022

From BioRestorative Therapies, Inc

Via GlobeNewswire

EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease ↗

December 05, 2022

BioRestorative Therapies, Inc (NASDAQ: BRTX), a stem cell-based therapies clinical-stage company, forged an agreement with Regenexx, LLC, under which BRTX gets exclusive license rights for intellectual...

Via Benzinga

BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference

November 29, 2022

Via Investor Brand Network

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 23, 2022

Via Benzinga

BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

November 16, 2022

From BioRestorative Therapies, Inc

Via GlobeNewswire

Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

November 15, 2022

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

Via FinancialNewsMedia

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

November 10, 2022

By Faith Ashmore, Benzinga

Via News Direct

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

November 10, 2022

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

Via TheNewswire.com

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.